Ohsu Knight Cancer Institute
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
Examining Arts As Targeted Elements of Childhood Cancer Treatment, CREATe Trial
Not Applicable
Recruiting
- Conditions
- Malignant Solid NeoplasmHematopoietic and Lymphatic System Neoplasm
- Interventions
- Other: Media InterventionProcedure: DiscussionProcedure: Art TherapyOther: Survey Administration
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 72
- Registration Number
- NCT06342453
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
BEST-RPP Pilot: Screening for Esophageal Cancer in Rural Oregon Without an Endoscopy
Active, not recruiting
- Conditions
- Esophageal Cancer
- Interventions
- Device: Screening with swallowable esophageal cell-collection devices (SECD)
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 110
- Registration Number
- NCT06335966
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmRecurrent Malignant Solid NeoplasmRefractory Malignant Solid Neoplasm
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission Tomography
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 38
- Registration Number
- NCT06320405
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma
Phase 1
Recruiting
- Conditions
- High Grade B-Cell LymphomaDiffuse Large B-Cell Lymphoma
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Bone Marrow Aspiration and BiopsyProcedure: Computed TomographyProcedure: EchocardiographyProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition ScanProcedure: Positron Emission Tomography
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT06249191
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA, IIB, or IIIA Melanoma
Phase 2
Recruiting
- Conditions
- Clinical Stage IIA Cutaneous Melanoma AJCC v8Clinical Stage IIB Cutaneous Melanoma AJCC v8Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
- Interventions
- Drug: Placebo AdministrationProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingOther: Electronic Health Record Review
- First Posted Date
- 2023-12-05
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 150
- Registration Number
- NCT06157099
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Use of Indocyanine Green in Pancreas Surgery
Recruiting
- Conditions
- Pancreatic Carcinoma
- Interventions
- Other: Non-Interventional Study
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 55
- Registration Number
- NCT06084013
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
An Exercise Prehabilitation Intervention for Improving Mobility and Recovery Outcomes in Patients Undergoing Head and Neck Cancer Surgery
Not Applicable
Recruiting
- Conditions
- Head and Neck Carcinoma
- Interventions
- Other: Electronic Health Record ReviewOther: Exercise InterventionOther: Medical Device Usage and EvaluationOther: Survey Administration
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT06079697
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients with Esophageal Cancer
Phase 2
Recruiting
- Conditions
- Atrial FibrillationEsophageal Carcinoma
- Interventions
- Other: Saline
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 90
- Registration Number
- NCT06067438
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
EMBRACE: Exercising Together
Phase 2
Recruiting
- Conditions
- Breast CarcinomaProstate Carcinoma
- Interventions
- Other: Exercise InterventionProcedure: Biospecimen CollectionOther: Educational Intervention
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 400
- Registration Number
- NCT06049355
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Internet-Based Lifestyle Intervention (iLIVE) to Eradicate Obese Frailty in Prostate Cancer Survivors
Not Applicable
Recruiting
- Conditions
- Prostate Carcinoma
- Interventions
- Other: Education InterventionOther: Internet-Based Exercise InterventionOther: Internet-Based Diet Intervention
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 250
- Registration Number
- NCT06011499
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸University of Alabama, Birmingham, Alabama, United States
© Copyright 2025. All Rights Reserved by MedPath